Allopregnanolone prodrug (Seaport Therapeutics)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAllopregnanolone prodrug (Seaport Therapeutics)
Drug Alias NameGlyphAlloGlyph-allopregnanoloneLYT-300SPT-300
ClassificationSmall molecules > Steroids
Mechanisms of ActionGamma-aminobutyric acid A receptor agonists
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsDepressive Disorder, MajorDepressive DisorderParkinson Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSeaport Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesSeaport TherapeuticsThe University Of ArizonaPuretech Health
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, MajorDepressive DisorderParkinson Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A